web analytics

COMT inhibitors for impulsive behaviors

Interests: Neurology
Published:
Lead Inventor: Jon Grant
Print or Save to PDF

SUMMARY

Drug repurposing to use catechol-O-methyl-transferase inhibitors for treating impulse control disorders, obsessive-compulsive disorders, and substance addictions

The Unmet Need: New options for treating impulsive behavior disorders

  • Impulse control disorders, Obsessive-Compulsive Disorder (OCD), and substance addictions are conditions that significantly impair the quality of life for millions of individuals worldwide. Current treatments often fall short due to their limited effectiveness, side effects, and the lack of FDA-approved drugs specifically targeting these behaviors. This unmet need has driven intense research into repurposing existing drugs, potentially offering new therapeutic avenues with better safety and efficacy profiles.

  • Current approaches to treating impulse control disorders, OCD, and substance addictions suffer from several notable limitations. Many available medications are not specifically approved by the FDA for these particular conditions, resulting in off-label use with varying degrees of success and potential legal and ethical concerns. Additionally, existing drugs often come with a range of side effects that impact patient compliance and overall treatment success. New research efforts are particularly crucial for OCD, which has limited pharmacological options, as the same drug class used currently shows varied efficacy. Consequently, there is a pressing need for more targeted and well-tolerated treatments to address these complex disorders effectively.

The Proposed Solution: Repurposing catechol-O-methyl-transferase inhibitors to treat impulse control disorders, OCD, and substance addictions

  • The faculty inventor repurposed existing catechol-O-methyl-transferase (COMT) inhibitors to treat impulse control disorders, obsessive-compulsive disorders (OCD), and substance addictions. Traditionally, this class of drugs has not been employed for these purposes. The novel approach leverages existing pharmacological agents to address mental health challenges for which there are currently no FDA-approved treatments. Ongoing research is being conducted to validate the efficacy of these repurposed drugs, specifically focusing on OCD, a realm where treatment options are particularly limited. This method relies on inhibiting the COMT enzyme, which plays a crucial role in the metabolism of neurotransmitters that influence behavior.

  • The uniqueness of this technology lies in its innovative application of already approved drugs to areas of unmet medical need. By repurposing COMT inhibitors, which have existing safety and efficacy profiles, the technology accelerates the process of finding effective treatments for disorders that are notoriously difficult to manage. Unlike entirely new medications that require extensive trials and approvals, these repurposed drugs can potentially reach the clinical market more swiftly. Moreover, this approach is cost-effective and leverages prior research, making it a highly efficient pathway in the therapeutic landscape. This differentiation is crucial in addressing the mental health crisis by providing quicker, reliable treatment options for patients suffering from impulse control and obsessive-compulsive disorders.

ADVANTAGES

ADVANTAGES

  • Treats behaviors without any FDA approved drugs.

  • Repurposes existing drugs effectively

APPLICATIONS

  • Impulse control disorders

  • Obsessive compulsive disorders

  • Substance addictions

  • Drug repurposing

 

PUBLICATIONS